Reliable Genotypic Tropism Tests for the Major HIV-1 Subtypes

Citations Over TimeTop 10% of 2015 papers

Abstract

Over the past decade antiretroviral drugs have dramatically improved the prognosis for HIV-1 infected individuals, yet achieving better access to vulnerable populations remains a challenge. The principal obstacle to the CCR5-antagonist, maraviroc, from being more widely used in anti-HIV-1 therapy regimens is that the pre-treatment genotypic "tropism tests" to determine virus susceptibility to maraviroc have been developed primarily for HIV-1 subtype B strains, which account for only 10% of infections worldwide. We therefore developed PhenoSeq, a suite of HIV-1 genotypic tropism assays that are highly sensitive and specific for establishing the tropism of HIV-1 subtypes A, B, C, D and circulating recombinant forms of subtypes AE and AG, which together account for 95% of HIV-1 infections worldwide. The PhenoSeq platform will inform the appropriate use of maraviroc and future CCR5 blocking drugs in regions of the world where non-B HIV-1 predominates, which are burdened the most by the HIV-1 pandemic.

Related Papers

• → Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice(2011)30 cited
• → Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient(2011)29 cited
• → TROCAI (Tropism Coreceptor Assay Information): a New Phenotypic Tropism Test and Its Correlation with Trofile Enhanced Sensitivity and Genotypic Approaches(2010)24 cited
• → Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc(2018)4 cited
• → HIV co-receptor tropism prediction remains stable over time in treatment-naïve patients(2015)